Wire Stories
-
499Tikehau Capital and Nikko Asset Management Enter Into Advanced Discussion to Form a Strategic Partnership in Asia
PARIS–(BUSINESS WIRE)–Regulatory News: Tikehau Capital (Paris:TKO), the global alternative asset management group, and Nikko Asset Management, one of Asia’s largest asset...
-
444Mitsui Chemicals Develops Diffrar™ Optical Polymer Wafers for AR Glasses
The Lineup includes the world’s first 8-inch polymer wafer for AR glasses TOKYO–(BUSINESS WIRE)–Mitsui Chemicals, Inc. (Tokyo: 4183; President & CEO: HASHIMOTO...
-
370BELFOR Expands Service Portfolio in Thailand with TBCC
BANGKOK–(BUSINESS WIRE)–#BELFOR–BELFOR Thailand, the local arm of the global leader in damage restoration services, is set to diversify its operations by acquiring...
-
347
InnoCare Appoints Xin Fu as Chief Financial Officer
BEIJING–(BUSINESS WIRE)–InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today that the Company...
-
358Lydia AI Expands Reach in Korea Through Strategic Partnerships with Hecto Data and Tobecon
SEOUL, South Korea–(BUSINESS WIRE)–#canada–Lydia AI, a leading Canadian health AI company, is thrilled to announce its strategic collaborations with Hecto Data and...
-
499
InnoCare Announces Phase II Study Results of TYK2 Inhibitor ICP-332 Meet Primary Endpoint in Patients with Atomic Dermatitis
BEIJING–(BUSINESS WIRE)–InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today...
-
762FARFETCH DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Farfetch Limited and Encourages Investors to Contact the Firm
NEW YORK–(BUSINESS WIRE)–#A–Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has...
-
412PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer
– PADCEV plus pembrolizumab approved based on groundbreaking EV-302 trial – – Confirmatory trial found PADCEV plus pembrolizumab nearly doubled median overall...
-
381CORRECTING and REPLACING Aurora, PTT Station, and Royal Umbrella are among the Winners of the 2023 – 2024 World Branding Awards
LONDON–(BUSINESS WIRE)–#worldbranding–Fourth paragraph, first sentence of release dated December 8, 2023, should read: Winners from Thailand include Thai Life Insurance, PTT Station,...
-
427
MOGU Announces Unaudited Financial Results for the Six Months Ended September 30, 2023
HANGZHOU, China–(BUSINESS WIRE)–MOGU Inc. (NYSE: MOGU) (“MOGU” or the “Company”), a KOL-driven online fashion and lifestyle destination in China, today announced its...
